OakChart

Hemab Therapeutics Holdings Inc

COAGHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

39.33+0.56 (1.44%)
2026-11-12 05:52 CET
Market cap
1,837.19 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-27.30 USD m
Free cash flow, TTM
-28.32 USD m
EPS diluted, TTM
-0.58
P/E
-
Compare

Price

COAG against its 20 and 50-day averages
2050beatmiss
30.0040.0050.002.1M4.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26COAGclose 39.3320-day 38.6550-day 37.2339.3352w high52w low

29.0% under the 52-week high of 55.42 on 14 Aug 2026. 52-week low 23.00 on 11 May 2026. Last 15 sessions, 48.2% high to low

Volume 1.38× normal · the line is the 50-bar volume average

Profile

COAG
52-week range, 50% of the way up
23.0055.42

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company. It engages in developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. The company was founded in 2020 and is headquartered in Cambridge, MA.

IndexRUT
Employees72
IPOMay 01, 2026
ATR, 14d3.54
Rel volume1.38
Short float11.46%
Insider own38.27%
Inst own61.23%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.84B
Enterprise Value1.41B
Income-
Sales-
Book/sh9.19
Cash/sh9.21
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees72
IPOMay 01, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B4.28
P/C4.27
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio33.86
Current Ratio33.86
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-2.53
EPS next Q-0.57
EPS this Y95.58%
EPS next Y15.30%
EPS next 5Y63.93%
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-123.60%
Sales Q/Q-
EarningsNov 10 BMO
EPS/Sales Surpr.-15.56% -

Ownership

Insider Own38.27%
Insider Trans0.73%
Inst Own61.23%
Inst Trans41.44%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA201.75%
SMA505.65%
SMA2005.85%
Trades-

Technical

Shs Outstand46.71M
Shs Float28.84M
Short Float11.46%
Short Ratio6.94
Short Interest3.31M
52W High55.42 -29.03%
52W Low23.00 71.00%
Volatility12.88% 8.86%
ATR (14)3.54
RSI (14)50.75
Beta-
Rel Volume1.38
Avg Volume476.18K
Volume655,797

Performance

Perf Week-12.77%
Perf Month31.98%
Perf Quarter-27.10%
Perf Half Y37.71%
Perf YTD45.67%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price61.71
Prev Close38.77
Price39.33
Change %1.44%

Analyst ratings

latest 8 of 8
DateActionAnalystRating changeTargetImplied
Nov 09, 2026InitiatedLLifeSci CapitalOutperform$65+65.3%
Oct 15, 2026InitiatedJJP MorganOverweight$70+78.0%
Oct 12, 2026InitiatedRRodman & RenshawBuy$56+42.4%
Jun 17, 2026InitiatedHH.C. WainwrightBuy$40+1.7%
May 26, 2026InitiatedWWedbushOutperform$42+6.8%
May 26, 2026InitiatedJJefferiesBuy$39-0.8%
May 26, 2026InitiatedGGoldmanBuy$36-8.5%
May 26, 2026InitiatedEEvercore ISIOutperform$50+27.1%

Peers

Mkt cap
TickerCompanyMkt cap
QUREuniQure NV1.72B
AGIOAgios Pharmaceuticals Inc1.96B
IRONDisc Medicine Inc3.97B
RAREUltragenyx Pharmaceutical Inc1.70B
NVONovo Nordisk ADR137.48B
KROSKeros Therapeutics Inc187.22M
SNYSanofi ADR115.43B
AAPGAscentage Pharma Group International ADR1.40B
BCRXBiocryst Pharmaceuticals Inc1.97B
ABCLAbCellera Biologics Inc3.90B

Insider trading

11 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
RA CAPITAL MANAGEMENT, L.P.10% OwnerJun 16 '26Buy24.9861,5231,536,8456,444,637Jun 17 06:24 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerJun 15 '26Buy24.896,146152,9746,383,114Jun 17 06:24 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMay 19 '26Buy24.973,80294,9366,375,972May 21 04:20 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMay 20 '26Buy24.9499624,8406,376,968May 21 04:20 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMay 12 '26Buy24.906,387159,0366,372,170May 14 05:21 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMay 11 '26Buy24.8139,869989,2266,365,783May 11 05:44 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMay 07 '26Buy24.469,906242,3236,324,431May 11 05:44 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerMay 08 '26Buy24.981,48337,0456,325,914May 11 05:44 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMay 04 '26Buy18.002,675,00048,150,0006,149,096May 06 07:16 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMay 05 '26Buy24.6397,4112,399,5466,246,507May 06 07:16 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMay 06 '26Buy24.6068,0181,673,3996,314,525May 06 07:16 PM

Held by

AUM
TickerCompanyAUM
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
FBCGFidelity Blue Chip Growth ETFAUM: 7.23B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
FFSMFidelity Fundamental Small-Mid Cap ETFAUM: 1.55B

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.580-0.502-0.5850.000.006
2026Q22026-08-11-0.800-0.733-0.5170.000.004
2026Q12026-06-03-23.490-23.245-0.4860.000.002
2026Q4---0.567--0.007
2027Q1---0.595--0.002
2027Q2---0.645--0.002
2027Q3---0.655--0.002
2027Q4---0.880--0.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-67.560--67.5600.00-
2026FY--2.986--0.00
2027FY--2.529--0.00
2028FY--3.171--1.93
2029FY--3.093--34.38
2030FY--1.653--146.26

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-104000.000.000.00
2026Q4S2026-10-144000.000.000.00
2026Q4S2026-08-113000.000.000.00
2026Q4S2026-06-163000.000.000.00
2026Q4S2026-06-032000.000.000.00
2026Q4S2026-05-252000.000.000.00
2026Q4S2026-05-221000.000.000.00
2026Q4R2026-11-10201-0.59-0.62-0.56
2026Q4R2026-11-03200-0.55-0.56-0.54
2026Q4R2026-10-25200-0.55-0.56-0.54
2026Q4R2026-10-14201-0.55-0.56-0.54
2026Q4R2026-08-11101-0.54-0.54-0.54
2026Q4R2026-07-13100-0.53-0.53-0.53
2026Q4R2026-06-03100-0.53-0.53-0.53

Estimate history

EPS, annual-24.247-31.817
Period20242025
EPS, quarterly-0.328-0.261-0.365-0.486-0.517-0.585
PeriodQ1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Sales, annual00
Period20242025
Sales, quarterly000000
PeriodQ1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Shares, annual2.0092.00946.712
Period20242025MRQ
Shares, quarterly46.70546.70546.70546.70546.70546.712
PeriodQ1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY
Total Revenue0.000.000.00
Cost of Goods Sold Incl. D&A0.080.300.25
Gross Profit-0.08-0.30-0.25
Selling, General and Administrative Excl. Other29.6869.8150.13
Research and Development24.6459.6341.41
Other Operating Expense0.000.000.00
Operating Income-29.76-70.12-50.38
Unusual Expense0.000.000.00
Net Income Before Taxes-26.61-64.14-48.52
Income Taxes0.69-0.230.18
Consolidated Net Income-27.30-63.91-48.71
Net Income From Continuing Operations-27.30-63.91-48.71
Net Income-27.30-63.91-48.71
EPS (Recurring)-0.58-31.82-24.25
EPS (Basic, Before Extraordinaries)-0.58-31.82-24.25
EPS (Diluted)-0.58-31.82-24.25
EBITDA-29.68-69.81-50.13
Non-Operating Income (Expense)3.155.981.86
Other After Tax Adjustments0.000.000.00
Stock Option Compensation Expense1.701.591.51
Shares Outstanding46.712.012.01
Market Capitalization1,837.191,837.19-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Total Revenue0.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.080.070.070.080.080.07
Gross Profit-0.08-0.07-0.07-0.08-0.08-0.07
Selling, General and Administrative Excl. Other29.6826.0023.5416.9815.9816.48
Research and Development24.6420.3419.4614.5512.8714.10
Other Operating Expense0.000.000.000.000.000.00
Operating Income-29.76-26.08-23.61-17.05-16.06-16.56
Unusual Expense0.000.000.000.000.000.00
Net Income Before Taxes-26.61-24.05-22.68-16.97-12.21-15.50
Income Taxes0.690.100.010.100.00-0.19
Consolidated Net Income-27.30-24.15-22.69-17.07-12.21-15.31
Net Income From Continuing Operations-27.30-24.15-22.69-17.07-12.21-15.31
Net Income-27.30-24.15-22.69-17.07-12.21-15.31
EPS (Recurring)-0.58-0.52-0.49-0.37-0.26-0.33
EPS (Basic, Before Extraordinaries)-0.58-0.52-0.49-0.37-0.26-0.33
EPS (Diluted)-0.58-0.52-0.49-0.37-0.26-0.33
EBITDA-29.68-26.00-23.54-16.98-15.98-16.48
Non-Operating Income (Expense)3.152.030.940.093.851.06
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense1.701.591.040.420.390.36
Shares Outstanding46.7146.7146.7146.7146.7146.71
Market Capitalization1,837.191,715.491,715.49---

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY
Cash & Short Term Investments185.4988.33
Short Term Receivables2.631.58
Inventories0.000.00
Other Current Assets4.443.33
Total Current Assets192.5593.23
Net Property, Plant & Equipment1.702.57
Total Investments and Advances0.000.00
Other Assets0.530.48
Total Assets194.7896.28
Short Term Debt Incl. Current Port. of LT Debt0.690.79
Accounts Payable5.733.16
Other Current Liabilities4.252.74
Total Current Liabilities10.686.68
Long Term Debt360.74204.85
Provision for Risks Charges0.000.00
Other Liabilities0.000.02
Total Liabilities371.42211.55
Non-Equity Reserves0.000.00
Preferred Stock - Carrying Value0.000.00
Common Equity-176.63-115.27
Total Shareholders Equity-176.63-115.27
Accumulated Minority Interest0.000.00
Total Equity-176.63-115.27
Total Liabilities & Stockholders Equity194.7896.28
Book Value Per Share-87.93-57.38
Tangible Book Value Per Share-87.93-57.38
Full-Time Employees72-
Price to Book Ratio4.28-
Return on Assets-43.92-
Return on Invested Capital-34.72-54.38
Quick Ratio18.0313.95
Current Ratio18.0313.95

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY
Net Income-27.30-63.91-48.71
Depreciation0.070.300.25
Other Funds (Non Cash)1.360.781.42
Funds from Operations-25.87-62.83-47.04
Extraordinary Item0.000.000.00
Changes in Working Capital-2.421.351.45
Cash from Operating Activities-28.29-61.48-45.59
Capital Expenditures-0.03-0.02-0.28
Net Assets From Acquisitions0.000.000.00
Sale of Fixed Assets and Businesses0.000.000.00
Purchase or Sale of Investments30.14-81.4762.19
Purchase of Investments0.00-252.50-53.29
Sale Or Maturity of Investments30.14171.03115.47
Other Uses0.000.000.00
Other Sources0.000.000.00
Cash from Investing Activities30.10-81.4861.90
Cash Dividends Paid0.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00
Change in Capital Stock0.05156.420.00
Repurchase of Common Pref Stock0.000.000.00
Sale of Common Pref Stock0.05156.420.00
Proceedsfrom Stock Options0.05156.420.00
Issuance or Reduction of Debt, Net0.00-0.12-0.10
Change in Long Term Debt0.00-0.12-0.10
Issuance of Long Term Debt0.000.000.00
Reduction of Long Term Debt0.00-0.12-0.10
Net Financing Active Other Cash Flow0.000.000.00
Other Financing Activities Uses0.000.000.00
Cash from Financing Activities0.05156.30-0.10
Exchange Rate Effect-0.080.220.00
Net Change in Cash1.7813.5716.21
Free Cash Flow-28.32-61.49-45.87
Deferred Taxes & Investment Tax Credit-0.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Cash & Short Term Investments430.24457.46163.53---
Short Term Receivables1.211.821.43---
Inventories0.000.000.00---
Other Current Assets6.714.724.47---
Total Current Assets438.16464.00169.43---
Net Property, Plant & Equipment1.411.501.59---
Total Investments and Advances0.000.000.00---
Other Assets3.152.294.24---
Total Assets442.71467.78175.26---
Short Term Debt Incl. Current Port. of LT Debt0.460.460.54---
Accounts Payable5.956.235.68---
Other Current Liabilities6.536.256.96---
Total Current Liabilities12.9412.9413.19---
Long Term Debt0.500.57360.69---
Provision for Risks Charges0.000.000.00---
Other Liabilities0.000.000.00---
Total Liabilities13.4413.51373.88---
Non-Equity Reserves0.000.000.00---
Preferred Stock - Carrying Value0.000.000.00---
Common Equity429.27454.27-198.62---
Total Shareholders Equity429.27454.27-198.62---
Accumulated Minority Interest0.000.000.00---
Total Equity429.27454.27-198.62---
Total Liabilities & Stockholders Equity442.71467.78175.26---
Book Value Per Share9.199.73-4.25---
Tangible Book Value Per Share9.199.73-4.25---
Price to Book Ratio4.28-8.64-8.64---
Return on Invested Capital-6.35-5.31-14.00---
Quick Ratio33.8635.8512.85---
Current Ratio33.8635.8512.85---

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Net Income-27.30-24.15-22.69-17.07-12.21-15.31
Depreciation0.070.070.070.080.080.07
Other Funds (Non Cash)1.360.860.660.68-0.780.77
Funds from Operations-25.87-23.22-21.96-16.31-12.91-14.46
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.420.580.38-0.08-2.421.43
Cash from Operating Activities-28.29-22.64-21.58-16.39-15.33-13.03
Capital Expenditures-0.03-0.02-0.110.000.00-0.02
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments30.14-107.41-15.730.0021.50-5.98
Purchase of Investments0.00-132.47-15.730.000.00-19.95
Sale Or Maturity of Investments30.1425.060.000.0021.5013.97
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities30.10-107.44-15.850.0021.50-5.99
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.05317.58-0.410.000.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.05317.58-0.410.000.000.00
Proceedsfrom Stock Options0.05317.58-0.410.000.000.00
Issuance or Reduction of Debt, Net0.000.00-0.05-0.03-0.03-0.03
Change in Long Term Debt0.000.00-0.05-0.03-0.03-0.03
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.00-0.05-0.03-0.03-0.03
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.05317.58-0.46-0.03-0.03-0.03
Exchange Rate Effect-0.080.00-0.220.000.000.00
Net Change in Cash1.78187.51-38.11-16.436.14-19.06
Free Cash Flow-28.32-22.66-21.70-16.39-15.33-13.05

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3011.46%3.3M28.8M458.83K
2026-10-1510.96%3.2M28.8M463.69K
2026-09-3011.75%3.4M28.8M449.38K
2026-09-159.16%2.6M28.8M380.97K
2026-08-317.31%2.1M28.8M350.81K
2026-08-147.05%2.0M28.8M319.47K
2026-07-316.13%2.0M33.3M375.79K
2026-07-154.99%1.7M33.3M350.12K
2026-06-305.16%1.7M33.3M359.12K
2026-06-154.07%1.4M33.3M337.12K
2026-05-293.16%1.0M32.5M422.55K
2026-05-152.34%0.8M32.5M636.45K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-11-06SCHEDULE 13G/ASEC
2026-09-254Statement of changes in beneficial ownership of securities2026-09-24SEC
2026-09-253Initial statement of beneficial ownership of securities2026-09-24SEC
2026-09-248-KCurrent report2026-09-24SEC
2026-08-14SCHEDULE 13GSEC
2026-08-14SCHEDULE 13GSEC
2026-08-12SCHEDULE 13GSEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-07SCHEDULE 13GSEC
2026-08-06SCHEDULE 13GSEC
2026-08-05SCHEDULE 13GSEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-15SEC
2026-05-214Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-05-2110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-218-KCurrent report2026-05-21SEC
2026-05-144Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-143Initial statement of beneficial ownership of securities2026-05-04SEC
2026-05-11SCHEDULE 13GSEC
2026-05-114Statement of changes in beneficial ownership of securities2026-05-07SEC
2026-05-11SCHEDULE 13DSEC
2026-05-118-KCurrent report2026-05-08SEC
2026-05-08SCHEDULE 13GSEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-064Statement of changes in beneficial ownership of securities2026-05-04SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-01-29SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-01-29SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-01-29SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-061.69M200
2026-0553.77M900
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
RA CAPITAL MANAGEMENT, L.P.16.72%
Novo Holdings A/S8.95%
FMR LLC7.97%
Capital International Investors7.72%
Deep Track Capital, LP7.71%
Siren, L.L.C.4.47%
Avoro Capital Advisors LLC4.12%
Bain Capital Life Sciences Investors, LLC3.53%
JPMORGAN CHASE & CO2.47%
VANGUARD CAPITAL MANAGEMENT LLC1.67%

Funds

Fund% owned
SMALLCAP World Fund Inc4.62%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.19%
JPMorgan Small Cap Growth Fund1.14%
Fidelity Growth Company Fund1.12%
Fidelity Stock Selector Small Cap Fund0.94%
Select Biotechnology Portfolio0.94%
Strategic Advisers Fidelity U.S. Total Stock Fund0.88%
Fidelity Series Small Cap Opportunities Fund0.57%
Fidelity Blue Chip Growth Fund0.51%
T. Rowe Price Health Sciences Fund, Inc.0.44%

OakChart. COAG. Cached 15 minutes.

Some panels did not load: news.